# Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

> **NCT07116746** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Arthrosi Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Gout
- Gouty Arthritis
- Hyperuricemia
- Gout Chronic
- Refractory Gout
- Uncontrolled Gout
- Tophaceous Gout

## Interventions

- **DRUG:** AR882 75 mg
- **DRUG:** XOI Low Dose
- **DRUG:** XOI High Dose

## Key facts

- **NCT ID:** NCT07116746
- **Lead sponsor:** Arthrosi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2026-11
- **Final completion:** 2027-02
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07116746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07116746, "Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT07116746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*